Interpretation of the Group Standard Specifications for the Construction of Tuberculosis Preventive Treatment Clinics in Primary Medical Institutions

doi:10.19982/j.issn.1000-6621.20260015

Abstract

Abstract:

Specifications for the Construction of Tuberculosis Preventive Treatment Clinics in Primary Medical Institutions (T/CHATA—052—2025) is a group standard issued by the Chinese Antituberculosis Association on September 25, 2025, and took effect on the same day. This standard mainly covers the construction conditions for tuberculosis preventive treatment clinics in primary medical and health institutions. It clarifies the norms regarding the clinics’ service targets, service contents and construction effect evaluation, providing a reference for primary medical and health institutions to deliver tuberculosis preventive treatment services. To facilitate the grassroots staff in accurately understanding and standardizing the application of this standard, this paper elaborates on its compilation background, main contents, formulation basis and application. It thereby provides technical guidance for the standardized construction and operation of the tuberculosis preventive treatment clinics at the grassroots level.

Key words: Tuberculosis, Preventive Health Services, Specifications, Reference Standards

CLC Number:

R521
R183

Ren Feilin, Jin Meihua, Tong Zhaowei, Zheng Pingming. Interpretation of the Group Standard Specifications for the Construction of Tuberculosis Preventive Treatment Clinics in Primary Medical Institutions[J]. Chinese Journal of Antituberculosis, 2026, 48(9): 1259-1265. doi: 10.19982/j.issn.1000-6621.20260015

References 29

[1]	Getahun H, Matteelli A, Chaisson R E, et al. Latent Mycobacterium tuberculosis infection[J]. N Engl J Med, 2015, 372(22):2127-2135. doi:10.1056/NEJMra1405427.
[2]	Stagg H R, Zenner D, Harris R J, et al. Treatment of latent tuberculosis infection:a network meta-analysis[J]. Ann Intern Med, 2014, 161(6):419-428. doi:10.7326/M14-1019.
[3]	World Health Organization. WHO consolidated guidelines on tuberculosis:Module 1:prevention:tuberculosis preventive treatment[R]. Geneva: World Health Organization, 2020.
[4]	郭同磊, 辛赫男, 高磊. 《世界卫生组织结核病整合指南模块1:结核病预防性治疗》解读[J]. 中国防痨杂志, 2023, 45(8):723-727. doi:10.19982/j.issn.1000-6621.20230199.
[5]	Houben R, Dodd P. The global burden of latent tuberculosis infection:a re-estimation using mathematical modelling[J]. PLoS Med, 2016, 13(10):e1002152. doi:10.1371/journal.pmed.1002152.
[6]	马艳, 陆伟, 高磊, 等. 终止结核病流行须加强结核分枝杆菌潜伏感染高危人群筛查和预防性治疗的管理[J]. 中国防痨杂志, 2022, 44(3): 209-214. doi:10.19982/j.issn.1000-6621.20220008.
[7]	沈鑫, 肖文静, 潘启超, 等. 加强潜伏感染管理,加速结核病疫情下降[J]. 上海预防医学, 2023, 35(3):199-202. doi:10.19428/j.cnki.sjpm.2023.22915.
[8]	中华人民共和国国家卫生健康委员会办公厅. 中国结核病预防控制工作技术规范(2020年版)[EB]. 国卫办疾控函〔2020〕279号.2020-04-02.
[9]	徐彩红, 赵雁林. 中国结核病预防性治疗指南[M]. 北京: 人民卫生出版社, 2023.
[10]	丁厅厅, 许兴龙, 李霞, 等. 基层医疗卫生机构开设结核病预防性治疗门诊的SWOT分析[J]. 中国卫生质量管理, 2025, 32(9):107-110. doi:10.13912/j.cnki.chqm.2025.32.9.21.
[11]	Hartman-Adams H, Clark K, Juckett G. Update on latent tuberculosis infection[J]. Am Fam Physician, 2014, 89(11):889-896. doi:10.2332/allergolint.13-LE-0622. pmid: 25077395
[12]	Cui X, Gao L, Cao B. Management of latent tuberculosis infection in China:Exploring solutions suitable for high-burden countries[J]. Int J Infect Dis, 2020, 92s:S37-S40. doi:10.1016/j.ijid.2020.02.034.
[13]	Gao L, Lu W, Bai L, et al. Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study[J]. Retour au numéro, 2020, 71(7):1627-1634. doi:10.1016/S1473-3099(14)71085-0.
[14]	高磊, 张慧, 胡茂桂, 等. 基于多中心调查数据和空间统计模型的全国结核分枝杆菌潜伏感染率估算[J]. 中国防痨杂志, 2022, 44(1):54-59. doi:10.19982/j.issn.1000-6621.20210661.
[15]	成君, 赵雁林. 创建无结核社区终止结核病流行[J]. 中国防痨杂志, 2021, 43(11):1120-1124. doi:10.3969/j.issn.1000-6621.2021.11.004.
[16]	吴倩, 王伟, 张钰, 等. 浙江省无结核社区评价指标体系构建[J]. 中国防痨杂志, 2025, 47(3): 331-337. doi:10.19982/j.issn.1000-6621.20240412.
[17]	成君, 赵雁林. 无结核社区建设中的主动筛查策略[J]. 中国防痨杂志, 2024, 46(6): 605-612. doi:10.19982/j.issn.1000-6621.20230435.
[18]	郑平明, 金玫华, 丁忠明, 等. 浙江省湖州市“无结核城市”建设实践与思考[J]. 中国防痨杂志, 2024, 46(10):1193-1197. doi:10.19982/j.issn.1000-6621.20240142.
[19]	王大宽, 张彬, 刘自森, 等. 基层结核病预防性治疗门诊建设的探索与展望[J]. 中国防痨杂志, 2023, 45(5):442-445. doi:10.19982/j.issn.1000-6621.20230083.
[20]	中国防痨协会. 基层医疗卫生机构结核感染预防与控制指南(T/CHATA 018-2022)[EB].2022-02-24.
[21]	中国防痨协会. 结核分枝杆菌潜伏感染人群预防性治疗规范(T/CHATA 028-2022)[EB].2022-10-27.
[22]	中国防痨协会. 高危人群结核分枝杆菌潜伏感染检测及预防性治疗专家共识[J]. 中国防痨杂志, 2021, 43(9):874-878. doi:10.3969/j.issn.1000-6621.2021.09.004.
[23]	罗姚, 魏苏璟, 杨晶, 等. 公立医院数据安全风险治理路径研究[J]. 卫生经济研究, 2025, 42(3):71-74,78. doi:10.14055/j.cnki.33-1056/f.2025.03.021.
[24]	Maskit B, Gali P, Ayal R, et al. Identifying factors affecting latent tuberculosis treatment acceptance among healthcare workers: a retrospective analysis in a tertiary care centre[J]. BMJ Open, 2021, 11(9): e047444-e047444. doi:10.1136/bmjopen-2020-047444.
[25]	杨宇兰, 万彬, 赵霞, 等. 中国结核分枝杆菌潜伏感染预防性治疗接受度及影响因素Meta分析[J]. 结核与肺部疾病杂志, 2026, 7(1):21-29. doi:10.19983/j.issn.2096-8493.20250091.
[26]	李锦浩, 胡冬梅, 夏岚, 等. 结核潜伏感染者预防性治疗接受情况及影响因素[J]. 热带病与寄生虫学, 2025, 23(6):341-347. doi:10.20199/j.issn.1672-2302.2025.06.005.
[27]	World Health Organization. WHO consolidated guidelines on tuberculosis:Module 3: diagnosis:tests for tuberculosis infection[R]. Geneva: World Health Organization, 2022.
[28]	Anibarro L, Trigo M, Villaverde C, et al. Interferon-γ release assays in tuberculosis contacts:is there a window period?[J]. Eur Respir J, 2011, 37(1):215-217. doi:10.1183/09031936.00030610. pmid: 21205718
[29]	中华人民共和国国家卫生健康委员会办公厅, 中华人民共和国教育部办公厅. 关于印发中国学校结核病防控指南的通知[EB]. 国卫办疾控函〔2020〕910号.2020-10-16.